Semaglutide references, with the context attached

Start with the question you came with

These are the sources linked throughout Get Semaglutide Clear. A study, a product label and an FDA safety alert do different jobs. The notes below help you choose which one is worth opening for your question.

For appetite biology, Gabery and colleagues' pathway study looked at mice and rats. It helps explain how semaglutide affects food intake through the brain. It can't tell you how a person will feel or give a human success rate.

For digestive side effects, Wharton and colleagues' trial analysis brings together weight-management trial data. Symptoms were usually mild to moderate and often appeared during dose increases. That finding doesn't make a severe symptom harmless.

Weight, heart outcomes and what happened later

Wilding and colleagues' weight-management trial, STEP 1, compared semaglutide with a dummy injection in adults without diabetes. Participants had obesity, or overweight plus a related condition, and both groups received lifestyle support. It's the source for the 68-week weight comparison on our research page.

The STEP 1 follow-up looked at a subset after treatment and the trial's lifestyle support stopped. It supplies the average weight-regain finding for the group previously assigned semaglutide. It doesn't decide how long any individual needs treatment.

Lincoff and colleagues' heart-outcomes trial, SELECT, enrolled adults with established cardiovascular disease and overweight or obesity, without diabetes. It tracked cardiovascular death, nonfatal heart attack or nonfatal stroke together. The research page puts the event percentages beside the comparison over time so both measures are clear.

Batsis and colleagues' body-composition review covers trials across four related medicines. Weight loss included lean tissue as well as fat, and none of the included trials objectively measured physical function. That leaves a question about strength; it doesn't provide a semaglutide-only answer.

The exact product and its safety information

Wegovy (semaglutide) prescribing information covers its injection and tablets, approved uses, warnings and restrictions. Ozempic (semaglutide) injection information covers that injectable product. Ozempic and Rybelsus (semaglutide) tablets information covers those oral diabetes products; Wegovy tablets belong to the separate Wegovy label.

Labels help answer product-specific questions. They aren't a way to swap milligram amounts between products or choose a plan without a prescriber. The doses page explains why the names and forms matter.

FDA's compounding questions and answers explain why compounded medicines are not FDA-approved. FDA doesn't review their safety, effectiveness or quality before marketing. Research on an approved product can't fill that gap.

FDA's unapproved GLP-1 concerns include semaglutide salt forms. Its compounded semaglutide dosing-error alert describes measurement mistakes, including cases needing hospital care. Neither is a set of measuring instructions.

FDA's April 1, 2026 compounding-policy update explains restrictions after national shortages ended. Our prescription guide puts that dated explanation into plain language. It can't establish the legal status of a particular preparation.